Ge healthcare and sophia genetics to collaborate to match treatments to multimodal patient data and cancer type

Chicago and boston, july 6, 2021 /prnewswire/ -- ge healthcare and sophia genetics today announced that they have signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each patient's genomic profile and cancer type, helping to ensure the most effective and personalized treatment. the companies aim to develop new artificial intelligence (ai)-powered analytics and workflow solutions to serve both the clinical and biopharma markets.
GE Ratings Summary
GE Quant Ranking